Rapid-acting antidepressants.

[1]  R. McIntyre,et al.  Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  J. Callanan,et al.  Comparison of electroencephalogram (EEG) response to MDPV versus the hallucinogenic drugs MK-801 and ketamine in rats , 2019, Experimental Neurology.

[3]  K. Hashimoto,et al.  Increased expression of inwardly rectifying Kir4.1 channel in the parietal cortex from patients with major depressive disorder. , 2019, Journal of affective disorders.

[4]  S. Wilkinson,et al.  A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. , 2019, Drug discovery today.

[5]  S. Dursun,et al.  Ayahuasca: Psychological and Physiologic Effects, Pharmacology and 
Potential Uses in Addiction and Mental Illness , 2019, Current neuropharmacology.

[6]  Sara Mohamed,et al.  Sex Differences in the Temporal Neuromolecular and Synaptogenic Effects of the Rapid-acting Antidepressant Drug Ketamine in the Mouse Brain , 2019, Neuroscience.

[7]  K. Hashimoto,et al.  Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine , 2019, Pharmacology Biochemistry and Behavior.

[8]  Zhongming Chen,et al.  BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1 , 2019, Psychiatry Research.

[9]  A. Nugent,et al.  Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study , 2019, Psychiatry Research: Neuroimaging.

[10]  M. Banks,et al.  Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. , 2019, Experimental and clinical psychopharmacology.

[11]  S. Thompson,et al.  Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. , 2019, Annual review of pharmacology and toxicology.

[12]  K. Hashimoto,et al.  An update on ketamine and its two enantiomers as rapid-acting antidepressants , 2018, Expert review of neurotherapeutics.

[13]  S. Chaki,et al.  Is the History Repeated? Can (2R,6R)-Hydroxynorketamine be Another Antidepressant? , 2018, Journal of experimental neuroscience.

[14]  F. McMahon,et al.  Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression , 2018, Translational Psychiatry.

[15]  T. Gould,et al.  Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine , 2018, Journal of psychopharmacology.

[16]  C. Zarate,et al.  Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments , 2018, The international journal of neuropsychopharmacology.

[17]  Dan T. Rosenbaum,et al.  Microdosing psychedelics: personality, mental health, and creativity differences in microdosers , 2018, Psychopharmacology.

[18]  Matthew W. Johnson,et al.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act , 2018, Neuropharmacology.

[19]  K. Hashimoto,et al.  Comparison of rapid and long-lasting antidepressant effects of negative modulators of α5-containing GABAA receptors and (R)‑ketamine in a chronic social defeat stress model , 2018, Pharmacology Biochemistry and Behavior.

[20]  A. Yli-Hankala,et al.  Cortical Excitability and Activation of TrkB Signaling During Rebound Slow Oscillations Are Critical for Rapid Antidepressant Responses , 2018, Molecular Neurobiology.

[21]  J. Krystal,et al.  The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? , 2018, Pharmacology & therapeutics.

[22]  K. Nakazawa,et al.  AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine , 2018, Biological Psychiatry.

[23]  Andrzej Pilc,et al.  The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice , 2018, Neuropharmacology.

[24]  P. Witt-Enderby,et al.  DARK Classics in Chemical Neuroscience: Ibogaine. , 2018, ACS chemical neuroscience.

[25]  M. Rasenick,et al.  NMDA-receptor independent actions of ketamine: a new chapter in a story that’s not so old , 2018, Neuropsychopharmacology.

[26]  Yuko Fujita,et al.  Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model , 2018, Psychopharmacology.

[27]  J. Bischofberger,et al.  Dendrite-targeting interneurons control synaptic NMDA-receptor activation via nonlinear α5-GABAA receptors , 2018, Nature Communications.

[28]  M. Furey,et al.  Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder , 2018, The international journal of neuropsychopharmacology.

[29]  A. Pałucha-Poniewiera.  The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug. , 2018 .

[30]  Jaime E. C. Hallak,et al.  Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews , 2018, Expert review of clinical pharmacology.

[31]  F. Vollenweider,et al.  Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor , 2018, eLife.

[32]  L. Ferrucci,et al.  Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects , 2018, Psychopharmacology.

[33]  S. Salton,et al.  Role of a VGF/BDNF/TrkB Autoregulatory Feedback Loop in Rapid-Acting Antidepressant Efficacy , 2018, Journal of Molecular Neuroscience.

[34]  S. Vigod,et al.  Mortality risk associated with psychological distress and major depression: A population-based cohort study. , 2018, Journal of affective disorders.

[35]  S. Chaki,et al.  5-HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2/3 receptor antagonist in mice , 2018, Neuropharmacology.

[36]  T. Gould,et al.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms , 2018, Pharmacological Reviews.

[37]  P. Xie,et al.  Mechanisms of ketamine on mice hippocampi shown by gas chromatography–mass spectrometry-based metabolomic analysis , 2018, Neuroreport.

[38]  M. Rasenick,et al.  NMDAR-independent, cAMP-dependent antidepressant actions of ketamine , 2018, Molecular Psychiatry.

[39]  D. E. Olson,et al.  Psychedelics Promote Structural and Functional Neural Plasticity , 2018, Cell reports.

[40]  J. Witkin,et al.  Rapid-Acting Antidepressants. , 2018, Current pharmaceutical design.

[41]  D. B. Rawlins,et al.  Biopharmaceutical Characterization and Oral Efficacy of a New Rapid Acting Antidepressant Ro 25-6981. , 2018, Journal of pharmaceutical sciences.

[42]  N. Galvão-Coelho,et al.  Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls , 2018, Front. Psychiatry.

[43]  K. Hashimoto,et al.  (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice , 2018, Neuropsychopharmacology.

[44]  J. Ramos-Quiroga,et al.  Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review , 2018, CNS Drugs.

[45]  L. Giner,et al.  A Review on the General Stability of Mood Disorder Diagnoses Along the Lifetime , 2018, Current Psychiatry Reports.

[46]  Facundo Carrillo,et al.  Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. , 2018, Journal of affective disorders.

[47]  C. Martelli,et al.  Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety , 2018, Journal of psychopharmacology.

[48]  Hanjie Yu,et al.  Vesicular glutamate transporter 1 (VGLUT1)-mediated glutamate release and membrane GluA1 activation is involved in the rapid antidepressant-like effects of scopolamine in mice , 2018, Neuropharmacology.

[49]  T. Gould,et al.  Mechanisms of ketamine action as an antidepressant , 2018, Molecular Psychiatry.

[50]  S. Sogabe,et al.  HBT1, a Novel AMPA Receptor Potentiator with Lower Agonistic Effect, Avoided Bell-Shaped Response in In Vitro BDNF Production , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[51]  Hailan Hu,et al.  Ketamine blocks bursting in the lateral habenula to rapidly relieve depression , 2018, Nature.

[52]  Hailan Hu,et al.  Astroglial Kir4.1 in the lateral habenula drives neuronal bursts in depression , 2018, Nature.

[53]  R. Duman,et al.  Rapid-Acting Antidepressants: Mechanistic Insights and Future Directions , 2018, Current Behavioral Neuroscience Reports.

[54]  Xiang Cai,et al.  Protein kinase A mediates scopolamine-induced mTOR activation and an antidepressant response. , 2018, Journal of affective disorders.

[55]  Xia Li,et al.  Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice , 2018, Psychopharmacology.

[56]  David J. Nutt,et al.  Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression , 2018, Front. Pharmacol..

[57]  P. Stanton,et al.  Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects , 2018, The international journal of neuropsychopharmacology.

[58]  K. Hashimoto,et al.  Mechanistic Target of Rapamycin–Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model , 2018, Biological Psychiatry.

[59]  R. Duman,et al.  Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine , 2018, Biological Psychiatry.

[60]  D. Nutt,et al.  Psychiatry & the psychedelic drugs. Past, present & future , 2017, Neuropharmacology.

[61]  D. Nutt,et al.  Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression , 2017, Neuropharmacology.

[62]  Yuko Fujita,et al.  Possible role of the gut microbiota–brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model , 2017, Translational Psychiatry.

[63]  Yuko Fujita,et al.  5-Hydroxytryptamine-Independent Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model , 2017, The international journal of neuropsychopharmacology.

[64]  K. Hashimoto,et al.  Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model , 2017, Scientific Reports.

[65]  D. Nutt,et al.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up , 2017, Psychopharmacology.

[66]  K. Hashimoto,et al.  Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine. , 2017, Journal of pharmacological sciences.

[67]  Evan J. Kyzar,et al.  Psychedelic Drugs in Biomedicine. , 2017, Trends in pharmacological sciences.

[68]  D. Nutt,et al.  Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression , 2017, Psychopharmacology.

[69]  Kevin Murphy,et al.  Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms , 2017, Scientific Reports.

[70]  E. Ballard,et al.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.

[71]  R. Kessler,et al.  Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis , 2017, JAMA psychiatry.

[72]  R. Duman,et al.  Novel rapid-acting antidepressants: molecular and cellular signaling mechanisms , 2017, Neuronal signaling.

[73]  K. Hashimoto,et al.  (R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine , 2017, Biological Psychiatry.

[74]  M. Popoli,et al.  Acute or Chronic? A Stressful Question , 2017, Trends in Neurosciences.

[75]  W. Bunney,et al.  A Circadian Genomic Signature Common to Ketamine and Sleep Deprivation in the Anterior Cingulate Cortex , 2017, Biological Psychiatry.

[76]  Hanjie Yu,et al.  The Requirement of L-Type Voltage-Dependent Calcium Channel (L-VDCC) in the Rapid-Acting Antidepressant-Like Effects of Scopolamine in Mice , 2017, The international journal of neuropsychopharmacology.

[77]  Jiang-Ping Liu,et al.  Inhibition of α5 subunit‐containing GABAA receptors facilitated spinal nociceptive transmission and plasticity , 2017, European journal of pain.

[78]  Matthew W. Johnson,et al.  Potential Therapeutic Effects of Psilocybin , 2017, Neurotherapeutics.

[79]  Zhongmin Zhang,et al.  The antidepressant-like effects of biperiden may involve BDNF/TrkB signaling-mediated BICC1 expression in the hippocampus and prefrontal cortex of mice , 2017, Pharmacology Biochemistry and Behavior.

[80]  S. Chaki.  mGlu2/3 Receptor Antagonists as Novel Antidepressants. , 2017, Trends in pharmacological sciences.

[81]  K. Martinowich,et al.  BDNF at the Synapse: Why Location Matters , 2017, Molecular Psychiatry.

[82]  JaneR . Taylor,et al.  GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine , 2017, Neuropsychopharmacology.

[83]  R. Higgs,et al.  Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice. , 2017, CNS & neurological disorders drug targets.

[84]  C. Zarate,et al.  New targets for rapid antidepressant action , 2017, Progress in Neurobiology.

[85]  K. Hashimoto,et al.  Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut–microbiota–brain axis , 2017, Translational Psychiatry.

[86]  S. Ide,et al.  Resolvin D1 and D2 Reverse Lipopolysaccharide-Induced Depression-Like Behaviors Through the mTORC1 Signaling Pathway , 2017, The international journal of neuropsychopharmacology.

[87]  D. McKinzie,et al.  Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects , 2017, Pharmacology Biochemistry and Behavior.

[88]  R. Raffa,et al.  What is the mechanism of Ketamine's rapid‐onset antidepressant effect? A concise overview of the surprisingly large number of possibilities , 2017, Journal of clinical pharmacy and therapeutics.

[89]  K. Hashimoto,et al.  Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[90]  P. Ornstein,et al.  Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression. , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[91]  Jodi L. Smith,et al.  In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist , 2017, Neuropharmacology.

[92]  J. Dorrian,et al.  Health Psychology in Australia , 2017 .

[93]  S. Shetty,et al.  The fibrinolytic system: A new target for treatment of depression with psychedelics. , 2017, Medical hypotheses.

[94]  S. Thompson,et al.  A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice , 2017, eNeuro.

[95]  D. David,et al.  Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice , 2017, Neuropharmacology.

[96]  P. Llorca,et al.  Investigational drugs in recent clinical trials for treatment-resistant depression , 2017, Expert review of neurotherapeutics.

[97]  D. Araujo,et al.  Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial , 2018, Psychological Medicine.

[98]  D. Lodge,et al.  Selective Pharmacological Augmentation of Hippocampal Activity Produces a Sustained Antidepressant-Like Response without Abuse-Related or Psychotomimetic Effects , 2017, The international journal of neuropsychopharmacology.

[99]  R. Duman,et al.  Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine , 2016, Current neuropharmacology.

[100]  C. Nilsson,et al.  Towards the Molecular Foundations of Glutamatergic-targeted Anti-depressants , 2016, Current neuropharmacology.

[101]  P. Stanton,et al.  The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant , 2016, Current Neuropharmacology.

[102]  K. Hashimoto,et al.  Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling , 2016, Scientific Reports.

[103]  Andrzej Pilc,et al.  Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495 , 2016, Neuropharmacology.

[104]  R. Duman,et al.  Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures , 2016, Neuropharmacology.

[105]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[106]  B. Schmidt,et al.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial , 2016, Journal of psychopharmacology.

[107]  K. Hashimoto,et al.  Depression-like phenotype by deletion of α7 nicotinic acetylcholine receptor: Role of BDNF-TrkB in nucleus accumbens , 2016, Scientific Reports.

[108]  D. Lodge,et al.  Hippocampal Perineuronal Nets Are Required for the Sustained Antidepressant Effect of Ketamine , 2016, The international journal of neuropsychopharmacology.

[109]  Laura M. Geffert,et al.  Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening , 2016, Pharmacology Biochemistry and Behavior.

[110]  Liang Tang,et al.  Neuroprotective effects of HTR1A antagonist WAY-100635 on scopolamine-induced delirium in rats and underlying molecular mechanisms , 2016, BMC Neuroscience.

[111]  T. Svensson,et al.  The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism , 2016, European Neuropsychopharmacology.

[112]  E. Carboni,et al.  Ketamine modulates catecholamine transmission in the bed nucleus of stria terminalis: The possible role of this region in the antidepressant effects of ketamine , 2016, European Neuropsychopharmacology.

[113]  E. Wauson,et al.  Kinase-mediated signaling cascades in mood disorders and antidepressant treatment , 2016, Journal of neurogenetics.

[114]  Michael R. Johnson,et al.  Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study , 2016, Neuropsychopharmacology.

[115]  K. Hashimoto.  Ketamine’s antidepressant action: beyond NMDA receptor inhibition , 2016, Expert opinion on therapeutic targets.

[116]  Daniel M. Rotroff,et al.  Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants , 2016, Translational psychiatry.

[117]  E. Lauterbach.  Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule. , 2016, Psychopharmacology bulletin.

[118]  J. Petrović,et al.  Molecular Mechanism and Clinical Relevance of Ketamine as Rapid‐Acting Antidepressant , 2016, Drug development research.

[119]  M. Picciotto,et al.  GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. , 2016, The Journal of clinical investigation.

[120]  James Rucker,et al.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.

[121]  S. Mitchell,et al.  The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[122]  Xi-Ping Huang,et al.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites , 2016, Nature.

[123]  K. Hashimoto,et al.  Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys , 2016, European Archives of Psychiatry and Clinical Neuroscience.

[124]  K. Behar,et al.  Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects , 2016, Molecular Psychiatry.

[125]  S. Chaki,et al.  The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN , 2016, Neuropsychopharmacology.

[126]  G. Aghajanian,et al.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants , 2016, Nature Medicine.

[127]  K. Hashimoto,et al.  Serum n-3 polyunsaturated fatty acids and psychological distress in early pregnancy: Adjunct Study of Japan Environment and Children's Study , 2016, Translational Psychiatry.

[128]  J. Riba,et al.  Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study , 2016, Journal of clinical psychopharmacology.

[129]  T. Rantamäki,et al.  Antidepressant drug action — From rapid changes on network function to network rewiring , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[130]  B. Dean,et al.  The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment? , 2015, Current neuropharmacology.

[131]  P. Stanton,et al.  The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus , 2015, Neuroscience.

[132]  Andrea Navarria,et al.  Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors , 2015, Neurobiology of Disease.

[133]  R. Schwarcz,et al.  The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[134]  K. Hashimoto,et al.  R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects , 2015, Translational Psychiatry.

[135]  Judith E. Hall,et al.  Ketamine amplifies induced gamma frequency oscillations in the human cerebral cortex , 2015, European Neuropsychopharmacology.

[136]  E. Seifritz,et al.  Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations , 2015, Psychopharmacology.

[137]  S. Thompson,et al.  Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors , 2015, Neuropsychopharmacology.

[138]  J. Feldon,et al.  Radixin regulates synaptic GABAA receptor density and is essential for reversal learning and short-term memory , 2015, Nature Communications.

[139]  K. Hashimoto,et al.  Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: A role for serotonin 5-HT1A and 5-HT2A receptors , 2015, European Neuropsychopharmacology.

[140]  Qinwen Wang,et al.  PI3K/AKT/mTOR Signaling-Mediated Neuropeptide VGF in the Hippocampus of Mice Is Involved in the Rapid Onset Antidepressant-Like Effects of GLYX-13 , 2015, The international journal of neuropsychopharmacology.

[141]  J. Roiser,et al.  Neural correlates of change in major depressive disorder anhedonia following open-label ketamine , 2015, Journal of psychopharmacology.

[142]  J. Witkin.  Commentary: obstacles to the discovery of medicines for psychiatric disorders in modern times. , 2015, CNS & neurological disorders drug targets.

[143]  B. Zemelman,et al.  Rapid antidepressants stimulate the decoupling of GABAB receptors from GIRK/Kir3 channels through increased protein stability of 14-3-3η , 2015, Molecular Psychiatry.

[144]  T. Passie,et al.  LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects , 2015, Journal of psychopharmacology.

[145]  A. Grace,et al.  Restoring Mood Balance in Depression: Ketamine Reverses Deficit in Dopamine-Dependent Synaptic Plasticity , 2014, Biological Psychiatry.

[146]  R. E. Higgs,et al.  M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[147]  J. Roiser,et al.  Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression , 2014, Translational Psychiatry.

[148]  Daniel Z Lieberman,et al.  The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. , 2014, Journal of affective disorders.

[149]  S. Chaki,et al.  Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats , 2014, Behavioural Brain Research.

[150]  Mark D. Miller,et al.  Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. , 2014, The Journal of clinical psychiatry.

[151]  T. Passie,et al.  Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases , 2014, The Journal of nervous and mental disease.

[152]  Michael K Parides,et al.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. , 2014, JAMA psychiatry.

[153]  K. Hashimoto,et al.  R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine , 2014, Pharmacology Biochemistry and Behavior.

[154]  Nanxin Li,et al.  Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses , 2013, Biological Psychiatry.

[155]  M. Quirk,et al.  Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects , 2013, Molecular Psychiatry.

[156]  Carlos A. Zarate,et al.  A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression , 2013, Biological Psychiatry.

[157]  D. Nutt,et al.  Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression? , 2013, Journal of psychopharmacology.

[158]  M. Furey,et al.  Antidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review , 2013, Biological Psychiatry.

[159]  E. Kavalali,et al.  The Role of Eukaryotic Elongation Factor 2 Kinase in Rapid Antidepressant Action of Ketamine , 2013, Biological Psychiatry.

[160]  J. Rybakowski,et al.  Possible usefulness of tianeptine in treatment-resistant depression , 2013, International journal of psychiatry in clinical practice.

[161]  C. Pae,et al.  Tianeptine combination for partial or non‐response to selective serotonin re‐uptake inhibitor monotherapy , 2013, Psychiatry and clinical neurosciences.

[162]  P. Stanton,et al.  GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects , 2013, Neuropsychopharmacology.

[163]  G. Tononi,et al.  Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. , 2013, The international journal of neuropsychopharmacology.

[164]  H. Onoe,et al.  Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice , 2013, Neuropharmacology.

[165]  E. Peselow,et al.  Scopolamine as an Antidepressant: A Systematic Review , 2013, Clinical neuropharmacology.

[166]  C. Lyketsos,et al.  Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease , 2012, International Psychogeriatrics.

[167]  J. Krystal,et al.  Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. , 2012, Schizophrenia bulletin.

[168]  S. Chaki,et al.  Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists , 2011, Neuropharmacology.

[169]  J. Witkin.  Commentary [the mood in the field of antidepressant drug discovery]. , 2011, CNS & neurological disorders drug targets.

[170]  D. Janowsky.  Serendipity Strikes Again: Scopolamine as an Antidepressant Agent in Bipolar Depressed Patients , 2011, Current psychiatry reports.

[171]  J. A. Boer,et al.  The cholinergic system and depression , 2011, Behavioural Brain Research.

[172]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[173]  J. Weiss,et al.  Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum. , 2011, The international journal of neuropsychopharmacology.

[174]  C. Grob,et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.

[175]  S. Chaki,et al.  AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell , 2010, Neurochemistry International.

[176]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[177]  D. Luckenbaugh,et al.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.

[178]  G. Nowak,et al.  The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test , 2010, Amino Acids.

[179]  K. Hsu,et al.  Activation of muscarinic acetylcholine receptors induces a nitric oxide-dependent long-term depression in rat medial prefrontal cortex. , 2010, Cerebral cortex.

[180]  J. Greer,et al.  Selective Antagonism of Opioid‐Induced Ventilatory Depression by an Ampakine Molecule in Humans Without Loss of Opioid Analgesia , 2010, Clinical pharmacology and therapeutics.

[181]  P. Skolnick,et al.  Glutamate-based antidepressants: 20 years on. , 2009, Trends in pharmacological sciences.

[182]  P. Popik,et al.  Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. , 2009, Journal of affective disorders.

[183]  A. D. Rodrigues,et al.  In Vitro and in Vivo Properties of 3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA Receptor α5 Subtype-Selective Inverse Agonist , 2009, Journal of Pharmacology and Experimental Therapeutics.

[184]  G. Sanacora,et al.  Targeting glial physiology and glutamate cycling in the treatment of depression. , 2009, Biochemical pharmacology.

[185]  B. Dean,et al.  Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. , 2009, Journal of affective disorders.

[186]  R. Howland.  The antidepressant effects of anticholinergic drugs. , 2009, Journal of psychosocial nursing and mental health services.

[187]  M. Krams,et al.  An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder , 2008, Journal of clinical psychopharmacology.

[188]  N. Scherbaum,et al.  Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy , 2008, Journal of clinical psychopharmacology.

[189]  P. Skolnick.  AMPA Receptors: A Target for Novel Antidepressants? , 2008, Biological Psychiatry.

[190]  L. Iversen.  The Monoamine Hypothesis of Depression , 2008 .

[191]  B. Moghaddam,et al.  NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons , 2007, The Journal of Neuroscience.

[192]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[193]  M. Furey,et al.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. , 2006, Archives of general psychiatry.

[194]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[195]  W. Drevets,et al.  Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. , 2006, Archives of general psychiatry.

[196]  R. Duman,et al.  A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.

[197]  E. Nisenbaum,et al.  A role for AMPA receptors in mood disorders. , 2006, Biochemical pharmacology.

[198]  S. Chaki,et al.  A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell , 2006, Neuroscience Letters.

[199]  S. Chaki,et al.  AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist , 2005, Brain Research.

[200]  S. Chaki,et al.  Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors , 2005, Neuroscience Letters.

[201]  P. Érdi,et al.  Modulation of septo-hippocampal θ activity by GABAA receptors: an experimental and computational approach 1 1 Supplementary data associated with this article can be found at doi:10.1016/j.neuroscience.2004.03.043. , 2004, Neuroscience.

[202]  R. Traub,et al.  Alpha 5 subunit-containing GABAA receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro. , 2004, The Journal of physiology.

[203]  Alan Frazer,et al.  Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression , 2004, Neuropsychopharmacology.

[204]  V. Novotny,et al.  P.1.132 First signs of improvement with tianeptine in the treatment of depression: An analysis of a double-blind study versus fluoxetine , 2003, European Neuropsychopharmacology.

[205]  K. Marthak,et al.  Olanzapine and fluoxetine combination in severe or resistant depression , 2003, Indian journal of psychiatry.

[206]  D. Lorrain,et al.  Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 , 2003, Neuroscience.

[207]  P. Greengard,et al.  Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[208]  B. Moghaddam,et al.  NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys , 2002, Synapse.

[209]  N. Harada,et al.  Cholinergic Neuronal Modulation Alters Dopamine D2Receptor Availability In Vivo by Regulating Receptor Affinity Induced by Facilitated Synaptic Dopamine Turnover: Positron Emission Tomography Studies with Microdialysis in the Conscious Monkey Brain , 2000, The Journal of Neuroscience.

[210]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[211]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.

[212]  D. Brocks.  Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. , 1999, Journal of Pharmacy & Pharmaceutical Sciences.

[213]  R. Mckernan,et al.  Autoradiographic localization of α5 subunit-containing GABAA receptors in rat brain , 1999, Brain Research.

[214]  J. McGinty,et al.  Muscarinic receptors regulate extracellular glutamate levels in the rat striatum: an in vivo microdialysis study. , 1998, The Journal of pharmacology and experimental therapeutics.

[215]  P. Willner.  The mesolimbic dopamine system as a target for rapid antidepressant action , 1997, International clinical psychopharmacology.

[216]  J. Kelsoe,et al.  No antidepressant effect of biperiden compared with placebo in depression: A double-blind 6-week clinical trial , 1995, Psychiatry Research.

[217]  S. Lukas,et al.  Buprenorphine treatment of refractory depression. , 1995, Journal of clinical psychopharmacology.

[218]  P. Skolnick,et al.  Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. , 1990, European journal of pharmacology.

[219]  H. Groenewegen,et al.  The distribution and compartmental organization of the cholinergic neurons in nucleus accumbens of the rat , 1989, Neuroscience.

[220]  D. Nichols,et al.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. , 1986, Journal of psychoactive drugs.

[221]  James V. Hinrichs,et al.  Ketamine: behavioral effects of subanesthetic doses. , 1984, Journal of clinical psychopharmacology.

[222]  S. Kasper,et al.  The Anticholinergic Biperiden in Depressive Disorders , 1981, Pharmacopsychiatria.

[223]  A. Phillips,et al.  Long-term deficits in stimulation-induced behaviors and self-stimulation after 6-hydroxydopamine administration in rats. , 1976, Behavioral biology.

[224]  D. Janowsky,et al.  A cholinergic-adrenergic hypothesis of mania and depression. , 1972, Lancet.

[225]  C. Savage.  Lysergic acid diethylamide; a clinical-psychological study. , 1952, The American journal of psychiatry.

[226]  S. Chaki.  mGlu2/3 receptor antagonists. , 2019, Advances in pharmacology.

[227]  D. De Gregorio,et al.  d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. , 2018, Progress in brain research.

[228]  K. Raab-Graham,et al.  Engaging homeostatic plasticity to treat depression , 2018, Molecular Psychiatry.

[229]  D. Araujo,et al.  Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. , 2015, Revista brasileira de psiquiatria.

[230]  Toshiaki Saitoh,et al.  Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats. , 2015, Biological & pharmaceutical bulletin.

[231]  J. Price,et al.  Neurocircuitry of Mood Disorders , 2010, Neuropsychopharmacology.

[232]  E. Nisenbaum,et al.  Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy , 2010 .

[233]  S. Koslow,et al.  Onset of antidepressant activity: Reexamining the structure of depression and multiple actions of drugs , 1996, Depression and anxiety.

[234]  W. Richards,et al.  LSD-assisted psychotherapy in patients with terminal cancer. , 1973, International pharmacopsychiatry.

[235]  W. Richards,et al.  LSD-assisted psychotherapy with terminal cancer patients. , 1969, Current psychiatric therapies.